Principal Investigator: Dana van Bemmel
Funding Mechanism: Research Contract
ID number: HHSF223201300169P
Award Date: 3/26/2013
Institution: GenWay Biotech
The Tobacco Control Act mandates the regulation of tobacco products using a population health standard including both users and non-users of tobacco products. To help meet this mandate, the Population Assessment of Tobacco and Health (PATH) study -- a nationally representative, longitudinal cohort study that will survey tobacco product users, never users, and former users including youth aged 12-17 and adults aged 18 and older – is gathering data on tobacco product use, attitudes, and health conditions and is collecting biological specimens (buccal cells, urine, and blood) from consenting adults. GenWay Biotech, a company that specializes in bioinformatic analyses of protein targets, will measure biomarkers in a subset of these biological specimens. GenWay will measure fibrinogen antigen, IL-6, sICAM and F2-Isoprostane in approximately 150 participant blood or urine samples. These data will inform the development of final baseline study procedures related to the collection, shipment, processing, storage, and requisitioning of biospecimens.